—Classifying myelodysplastic syndrome and secondary acute myeloid leukemia by genetic mutations rather than strictly by blast count may allow more patients to be eligible for AML and MDS clinical ...
After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the ...
Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback